Translation of "Interstitial pneumonia" in German

Interstitial alveolitis/ pneumonia (can be fatal)

Acute respiratory distress syndrome, interstitial pneumonia and pulmonary fibrosis have rarely been reported.

Mycoplasma pneumoniae is the most common pathogen in community-acquired interstitial pneumonia.

Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported (see section 4.4).

Rare pulmonary undesirable effects, in particular interstitial pneumonia, have been reported after G-CSF administration.

Rare pulmonary undesirable effects, in particular interstitial pneumonia, have been reported after G- CSF administration.

Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration.

Rare pulmonary undesirable effects, in particular interstitial pneumonia, have been reported after GCSF administration.

Acute respiratory distress syndrome and cases of interstitial pneumonia/ pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported.

Sometimes acute interstitial pneumonia can happen occasionally which can even cause death of some patients.

Mild bronchiolitis, multifocal lesions and interstitial pneumonia with syncytia formation will develop.

There is a wide range of conditions that can lead to interstitial pneumonia in dogs.

Rare (1/ 10,000 to < 1/ 1,000) pulmonary adverse effects including interstitial pneumonia, pulmonary oedema, pulmonary infiltrates and pulmonary fibrosis have been reported.

Rare (? 1/ 10,000 to < 1/ 1,000) pulmonary adverse effects, in particular interstitial pneumonia, have been reported after G-CSF administration.

Blood tests that show changes in the way the liver is working, low levels of phosphate in the blood, increased blood clotting (including thrombosis of the veins, embolism in the lung), upper respiratory infections, pneumonia, interstitial lung disease, decreased number of white blood cells, decreased number of lymphocytes.

The most serious adverse reactions that may occur during filgrastim treatment include: anaphylactic reaction, serious pulmonary adverse events (including interstitial pneumonia and ARDS), capillary leak syndrome, severe splenomegaly/splenic rupture, transformation to myelodysplastic syndrome or leukaemia in SCN patients, GvHD in patients receiving allogeneic bone marrow transfer or peripheral blood cell progenitor cell transplant and sickle cell crisis in patients with sickle cell disease.

Cases of interstitial pneumonia/pneumonitis and interstitial lung disease, sometimes fatal have been reported with an unknown frequency (cannot be estimated from the available data) (see section 4.4).

There have been rare reports of acute diffuse infiltrative pulmonary disease of unknown aetiology such as pneumonitis, interstitial pneumonia, lung infiltration, and acute respiratory distress syndrome (ARDS) in patients receiving VELCADE (see section 4.8).

Rare pulmonary undesirable effects including interstitial pneumonia, pulmonary oedema and pulmonary infiltrates have been reported in some cases with an outcome of respiratory failure or adult respiratory distress syndrome (ARDS) which may be fatal (see section 4.4).

Acute respiratory distress syndrome and cases of interstitial pneumonia/pneumonitis, interstitial lung disease, pulmonary fibrosis and respiratory failure sometimes fatal have rarely been reported.

Other frequently (common) occurring adverse reactions are leukopenia, anaemia, thrombopenia, headache, tiredness, drowsiness, pneumonia, interstitial alveolitis/pneumonitis often associated with eosinophilia, oral ulcers, diarrhoea, exanthema, erythema and pruritus.

Rare pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after G-CSF administration (see section 4.8).

Pulmonary adverse reactions, in particular interstitial pneumonia, have been reported after administration of lipegfilgrastim (see section 4.8).